$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000162828023026768 Filed on August 02, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$123.6M	$117.7M
YoY Change	21.5%	13.86%
Cost Of Revenue	$1.645M	$1.574M
YoY Change	22.85%	19.6%
Gross Profit	$122.0M	$116.1M
YoY Change	21.48%	13.79%
Gross Profit Margin	98.67%	98.66%
Selling, General & Admin	$45.26M	$43.28M
YoY Change	28.72%	14.46%
% of Gross Profit	37.11%	37.27%
Research & Development	$45.52M	$43.28M
YoY Change	36.72%	31.84%
% of Gross Profit	37.32%	37.26%
Depreciation & Amortization	$100.0K	$186.0K
YoY Change	-48.72%	60.34%
% of Gross Profit	0.08%	0.16%
Operating Expenses	$90.78M	$86.56M
YoY Change	32.61%	22.54%
Operating Profit	$31.18M	$29.58M
YoY Change	-2.37%	-5.88%
Interest Expense	$5.200M	$3.347M
YoY Change	385.98%	431.27%
% of Operating Profit	16.68%	11.31%
Other Income/Expense, Net	$5.208M	$3.347M
YoY Change	386.73%	431.27%
Pretax Income	$36.39M	$32.93M
YoY Change	10.24%	2.71%
Income Tax	$5.000M	$5.402M
% Of Pretax Income	13.74%	16.4%
Net Earnings	$31.38M	$27.53M
YoY Change	-9.33%	0.42%
Net Earnings / Revenue	25.39%	23.39%
Basic Earnings Per Share	$0.31	$0.27
Diluted Earnings Per Share	$0.28	$0.25
COMMON SHARES
Basic Shares Outstanding	102.5M shares	101.6M shares
Diluted Shares Outstanding	111.1M shares	109.6M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$355.2M	$363.3M
YoY Change	-10.36%	-1.84%
Cash & Equivalents	$111.8M	$172.4M
Short-Term Investments	$243.4M	$190.9M
Other Short-Term Assets	$34.20M	$29.86M
YoY Change	65.38%	94.41%
Inventory	$7.513M	$6.915M
Prepaid Expenses
Receivables	$34.63M	$32.55M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$431.5M	$432.6M
YoY Change	-4.61%	3.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$302.0K	$648.0K
YoY Change	-62.3%	-24.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$59.60M	$0.00
YoY Change	1117.57%	-100.0%
Other Assets	$6.540M	$91.39M
YoY Change	28.71%	4883.04%
Total Long-Term Assets	$162.5M	$92.04M
YoY Change	100.98%	19.04%
TOTAL ASSETS
Total Short-Term Assets	$431.5M	$432.6M
Total Long-Term Assets	$162.5M	$92.04M
Total Assets	$594.0M	$524.6M
YoY Change	11.4%	5.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.71M	$7.976M
YoY Change	104.33%	-3.27%
Accrued Expenses	$69.63M	$65.60M
YoY Change	136.75%	165.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$121.9M	$93.06M
YoY Change	129.65%	89.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.50M	$9.952M
YoY Change	53.89%	99.8%
Total Long-Term Liabilities	$10.50M	$9.952M
YoY Change	53.89%	99.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$121.9M	$93.06M
Total Long-Term Liabilities	$10.50M	$9.952M
Total Liabilities	$132.3M	$103.0M
YoY Change	120.97%	90.63%
SHAREHOLDERS EQUITY
Retained Earnings	$371.2M	$339.8M
YoY Change	32.66%	38.59%
Common Stock	$722.5M	$695.9M
YoY Change	11.34%	11.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$461.7M	$421.6M
YoY Change
Total Liabilities & Shareholders Equity	$594.0M	$524.6M
YoY Change	11.4%	5.69%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	$31.38M	$27.53M
YoY Change	-9.33%	0.42%
Depreciation, Depletion And Amortization	$100.0K	$186.0K
YoY Change	-48.72%	60.34%
Cash From Operating Activities	$53.00M	$42.29M
YoY Change	57.51%	134.4%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$102.0K
YoY Change	-100.0%	-636.84%
Acquisitions
YoY Change
Other Investing Activities	-$109.6M	-$24.00M
YoY Change	2369.02%	-42.57%
Cash From Investing Activities	-$109.6M	-$24.10M
YoY Change	2188.1%	-42.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-3.900M	-145.8M
YoY Change	-72.07%	5188.61%
NET CHANGE
Cash From Operating Activities	53.00M	42.29M
Cash From Investing Activities	-109.6M	-24.10M
Cash From Financing Activities	-3.900M	-145.8M
Net Change In Cash	-60.50M	-127.6M
YoY Change	-506.12%	381.09%
FREE CASH FLOW
Cash From Operating Activities	$53.00M	$42.29M
Capital Expenditures	$0.00	$102.0K
Free Cash Flow	$53.00M	$42.18M
YoY Change	55.89%	133.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27356000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27356000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27398000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27398000	usd
	cort	Excise Tax Payable ExciseTaxPayable	1316000	usd
	cort	Excise Tax Payable ExciseTaxPayable	0	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	501842000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6540000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6359000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10966000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	716000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	15879000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	529584000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4497000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4823000	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	145428000	usd
CY2023Q2	cort	Treasury Stock Value Acquired Excise Tax TreasuryStockValueAcquiredExciseTax	1316000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11374000	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	198000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	27528000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	421614000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	375806000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6544000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7037000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10825000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1124000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	22797000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	407811000	usd
CY2022Q2	cort	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Vested StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockVested	6597000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9366000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10662000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-790000	usd
	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
	cort	Number Of Compounds NumberOfCompounds	1000	compound
CY2023Q2	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	6679000	usd
CY2022Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	7827000	usd
CY2023Q2	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	8998000	usd
CY2022Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	9204000	usd
CY2023Q2	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	15677000	usd
CY2022Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	17031000	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	8762000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	10931000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	6915000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6100000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4478000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4340000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4065000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3707000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	413000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	633000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	19488000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	89000	usd
CY2023Q2	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	15523000	usd
CY2022Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11098000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12579000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15511000	usd
CY2023Q2	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	1377000	usd
CY2022Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	2673000	usd
CY2023Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1316000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	0	usd
CY2023Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	668000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	434000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	590000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	638000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	783000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52179000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30799000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	259372000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	406670000	usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	600000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1800000	usd
	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P2Y
	cort	Marketable Securities Short Term Maximum Maturity Period MarketableSecuritiesShortTermMaximumMaturityPeriod	P1Y
	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P3M
CY2023Q2	cort	Loss Contingency Accrual Other LossContingencyAccrualOther	0	usd
CY2023Q2	cort	Loss Contingency Accrual Provision Other LossContingencyAccrualProvisionOther	0	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	usd
CY2023Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	297000	usd
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	155000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	155000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	310000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	297000	usd
CY2023Q2	cort	Lessee Short Term Lease Liability To Be Paid Remainder Of Fiscal Year LesseeShortTermLeaseLiabilityToBePaidRemainderOfFiscalYear	1100000	usd
CY2023Q2	cort	Lessee Short Term Lease Liability To Be Paid Year One LesseeShortTermLeaseLiabilityToBePaidYearOne	1100000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	34000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	56000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	126000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	120000	usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	11892000	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10662000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	23125000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	21487000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27356000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27356000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	27398000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	27398000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101964000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106289000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104908000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106151000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7626000	shares
CY2022Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9110000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	7584000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9071000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109590000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115399000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112492000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115222000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.24
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5400000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4700000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8700000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	700000	usd
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1100000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	9900000	usd
CY2023Q2	cort	Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance	2600000	usd
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-23-026768-index-headers.html	Edgar Link	pending
0001628280-23-026768-index.html	Edgar Link	pending
0001628280-23-026768.txt	Edgar Link	pending
0001628280-23-026768-xbrl.zip	Edgar Link	pending
cort-20230630.htm	Edgar Link	pending
cort-20230630.xsd	Edgar Link	pending
cort63023ex101.htm	Edgar Link	pending
cort63023ex102.htm	Edgar Link	pending
cort63023ex311.htm	Edgar Link	pending
cort63023ex312.htm	Edgar Link	pending
cort63023ex321.htm	Edgar Link	pending
cort63023ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
cort-20230630_def.xml	Edgar Link	unprocessable
cort-20230630_lab.xml	Edgar Link	unprocessable
cort-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
cort-20230630_cal.xml	Edgar Link	unprocessable
cort-20230630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2023 Q3 Form 10-Q Financial Statement

#000162828023026768 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2023 Q3 Form 10-Q Financial Statement

#000162828023026768 Filed on August 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort